EUR/USD 1.1541 ▼ 0.50%GBP/USD 1.3482 ▼ 0.33%USD/JPY 154.5248 ▲ 0.61%USD/CHF 0.8186 ▲ 0.26%EUR/CHF 0.9428 ▼ 0.44%BTC/USD 78,185.64 ▲ 1.75%ETH/USD 2,518.57 ▲ 1.67%SOL/USD 101.52 ▲ 2.24%XAU/USD 4,287.04 ▼ 1.41%EUR/USD 1.1541 ▼ 0.50%GBP/USD 1.3482 ▼ 0.33%USD/JPY 154.5248 ▲ 0.61%USD/CHF 0.8186 ▲ 0.26%EUR/CHF 0.9428 ▼ 0.44%BTC/USD 78,185.64 ▲ 1.75%ETH/USD 2,518.57 ▲ 1.67%SOL/USD 101.52 ▲ 2.24%XAU/USD 4,287.04 ▼ 1.41%
Finance Review DailyMARKETS • BUSINESS • ECONOMY
EILMELDUNG
Universal Health Services Lowers Full-Year Guidance as Exchange Headwinds Mount•ABM posts record Q3 2026 revenue of $2.3B, raises EPS outlook•Revenio Reports Q2 Profit Drop as Visionix Acquisition Weighs on Margins•Oil prices climb toward $100 as Middle East peace hopes fade•Bitcoin rally has more room as volatility shorts unwind, Two Prime CEO says•Universal Health Services Lowers Full-Year Guidance as Exchange Headwinds Mount•ABM posts record Q3 2026 revenue of $2.3B, raises EPS outlook•Revenio Reports Q2 Profit Drop as Visionix Acquisition Weighs on Margins•Oil prices climb toward $100 as Middle East peace hopes fade•Bitcoin rally has more room as volatility shorts unwind, Two Prime CEO says•
ADVERTISEMENT
LIVE-DESK·Globale Marktredaktion·Last updated 14s ago
ADVERTISEMENT
Novara — A Smarter Way to Access Global Markets
Märkte/DevisenArticle

Novartis Phase III trial results for del-desiran from the Avidity acquisition miss primary endpoints in treating myotonic dystrophy type 1

Finance Review Daily is tracking this developing story; additional confirmed specifics had not been verified at the time of publication.

SL
Sophie Laurent · FX & Rates Desk · 14 Sept 2026 · 15:57 · 1 Min. Lesezeit
Teilen
Novartis Phase III trial results for del-desiran from the Avidity acquisition miss primary endpoints in treating myotonic dystrophy type 1

Novartis Phase III trial results for del-desiran from the Avidity acquisition miss primary endpoints in treating myotonic dystrophy type 1.

Euro / US Dollar

EURUSD
Full profile →
1.1541▼ 0.50%
As of 13/09/2026, 21:00:00

Finance Review Daily is tracking this development following a report from the original source. Additional confirmed specifics had not been verified at the time of publication.

Dieser Artikel wurde mit KI-Unterstützung erstellt und von einer Finances-Review-Redakteurin bearbeitet.
ADVERTISEMENT
Artikel teilen
SL
Geschrieben von
Sophie Laurent
FX & Rates Desk

Sophie covers currency markets and central bank policy across Europe, with a focus on how rate decisions ripple through FX pairs. She has been tracking the ECB's policy path since the start of the current easing cycle.

Mehr von Sophie Laurent →
ADVERTISEMENT

Marktüberblick

Verzögert
EUR/USD1.1541▼ 0.50%GBP/USD1.3482▼ 0.33%USD/CHF0.8186▲ 0.26%BTC/USD78,185.64▲ 1.75%ETH/USD2,518.57▲ 1.67%XAU/USD4,287.04▼ 1.41%

Das könnte Sie auch interessieren

iBio’s obesity pipeline advances with long-acting antibody IBIO-610, Q3 2027 trial targets
Devisen

iBio’s obesity pipeline advances with long-acting antibody IBIO-610, Q3 2027 trial targets

Sophie Laurent · vor 1 Std.
ADVERTISEMENT